NGL Fine-Chem (NSE:NGLFINE) Total Liabilities: ₹2,163 Mil (As of Mar. 2026)

What is NGL Fine-Chem Total Liabilities?

NGL Fine-Chem NSE:NGLFINE +4.28% 78 Total Liabilities is ₹2,163 Mil as of Mar. 2026. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,821.59 (Modestly Overvalued). The stock has 8 warning signs investors should review.

NGL Fine-Chem's Total Liabilities for the quarter that ended in Mar. 2026 was ₹2,163 Mil.

NGL Fine-Chem's quarterly Total Liabilities declined from Sep. 2025 (₹1,839.22 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹2,162.66 Mil).

NGL Fine-Chem's annual Total Liabilities increased from Mar. 2024 (₹929.04 Mil) to Mar. 2025 (₹1,509.57 Mil) and increased from Mar. 2025 (₹1,509.57 Mil) to Mar. 2026 (₹2,162.66 Mil).

NGL Fine-Chem Total Liabilities Related Terms

NGL Fine-Chem Total Liabilities Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem Total Liabilities Chart

NGL Fine-Chem Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Total Liabilities

Get a 7-Day Free Trial

737.10

645.30

929.04

1,509.57

2,162.66

NGL Fine-Chem Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															1,509.57	0.00	1,839.22	0.00	2,162.66

78GF Score

NGL Fine-Chem Ltd NSE:NGLFINE

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NGL Fine-Chem Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NGL Fine-Chem's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1500.139	+	(564.033	+	98.491
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,163

Total Liabilities	=	Total Assets (A: Mar. 2026 )	-	Total Equity (A: Mar. 2026 )
	=	5454.958	-	3292.295
	=	2,163

NGL Fine-Chem's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1500.139	+	(564.033	+	98.491
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,163

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	5454.958	-	3292.295
	=	2,163

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of ₹2,163 Mil mean?

NGL Fine-Chem (NSE:NGLFINE) has a Total Liabilities of ₹2,163 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NGL Fine-Chem and its competitors.

Is NGL Fine-Chem's Total Liabilities too high?

NGL Fine-Chem's current Total Liabilities is ₹2,163 Mil. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does NGL Fine-Chem's Total Liabilities compare to LLY and JNJ?

NGL Fine-Chem's Total Liabilities of ₹2,163 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NGL Fine-Chem and its competitors. NGL Fine-Chem's current Total Liabilities is ₹2,163 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NGL Fine-Chem stock overvalued right now?

Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,821.59, compared to a current price of ₹3,224.60 — trading 14.3% above its estimated fair value. The current Total Liabilities is ₹2,163 Mil. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Total Liabilities is ₹2,163 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹3,224.60 is trading 14.3% above its estimated GF Value™ of ₹2,821.59. GuruFocus considers NGL Fine-Chem to be Modestly Overvalued.

Key valuation signals for NSE:NGLFINE:

Total Liabilities: ₹2,163 Mil
GF Value™: ₹2,821.59 vs. price of ₹3,224.60 (14.3% above fair value)
GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NGL Fine-Chem Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:507747 NSE:SAIPARENT BOM:524280 NSE:ACCPL NSE:QUESTLAB BOM:532815 NSE:SENORES BOM:500674 LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B AMGN GILD PFE BMY

Other Exchanges 524774:India

Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057

Website https://www.nglfinechem.com

NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.

78GF Score

Get the complete analysis for NSE:NGLFINE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,224.60

Price

₹2,821.59

GF Value

View NSE:NGLFINE Analysis

See Total Liabilities data for all stocks →